Global Blood Therapeutics to Host Investor Event on Friday, June 10 to Review GBT440 Data in Sickle Cell Disease Being Presented at the European Hematology Association's 21st Congress

Press Release

View printer-friendly version
<< Back
Global Blood Therapeutics to Host Investor Event on Friday, June 10 to Review GBT440 Data in Sickle Cell Disease Being Presented at the European Hematology Association's 21st Congress

SOUTH SAN FRANCISCO, Calif., June 2, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that it will host an investor webcast on Friday, June 10, 2016, at 1:30 p.m. CEST/7:30 a.m. ET, during which members of GBT's management team and distinguished experts Dr. H. Franklin Bunn of Harvard Medical School and Brigham and Women's Hospital, Dr. Paul Telfer of Barts Health NHS Trust and Queen Mary, University of London, and Dr. Wally R. Smith of Virginia Commonwealth University, will review the GBT440 data being presented at the European Hematology Association's (EHA) 21stCongress in Copenhagen. Please note the new date and time of the event. It was originally scheduled for Saturday, June 11 and is being rescheduled for Friday, June 10.

The EHA presentations will include additional data from the ongoing Phase 1/2 GBT440-001 study in sickle cell disease (SCD), including 90-day data from a cohort of patients taking 700 mg of GBT440, 28-day results from three dosing cohorts of GBT440 and additional data on the pharmacokinetics and pharmacodynamics of GBT440.

The investor event will be webcast live and available for replay from GBT's website at in the Investors & Media section.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF) and hereditary angioedema (HAE). To learn more, please visit:  

Forward-Looking Statements
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the therapeutic potential and safety profile of GBT440, our ability to receive data from our ongoing Phase 1/2 clinical study of GBT440, and our ability to initiate our pivotal program for GBT440 in SCD, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidate, and that drug-related adverse events may be observed in later stages of clinical development, along with those set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


To view the original version on PR Newswire, visit:

SOURCE Global Blood Therapeutics, Inc.

Myesha Edwards (investors), Global Blood Therapeutics, 650-351-4730,; or Ryan Flinn (media), BrewLife, 415-946-1059,